Memphasys secures early TGA approval for Felix system
Memphasys (ASX:MEM) has announced that its flagship Felix System has secured official approval from the Therapeutic Goods Administration.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Memphasys (ASX:MEM) has announced that its flagship Felix System has secured official approval from the Therapeutic Goods Administration.
Investment giant Challenger (ASX:CGF) confirmed it is in advanced discussions to acquire Pepper Money (ASX:PPM).
Plains All American Pipeline (NYSE:PAA), a leading midstream energy company focused on transportation, storage, and marketing of crude oil and natural gas liquids, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Baltimore-based Under Armour (NYSE:UAA) today reported fiscal third-quarter results that beat Wall Street expectations on an adjusted basis despite a significant GAAP net loss tied to non-recurring items.
Tether has made a $150 million strategic investment in Gold.com, acquiring about a 12% stake as it deepens its push into tokenised and physical gold.
Cynthia Lummis said banks should adopt stablecoins and crypto services rather than resist them, arguing digital assets offer new products and revenue opportunities for financial institutions.
Stellantis (NYSE:STLA) reported a significant recovery in its fourth-quarter global shipments on Friday, buoyed by a powerful 43% surge in North America that offset persistent cooling in the European market.
Multiliquid and Metalayer Ventures have launched an institutional liquidity facility that enables instant redemption of tokenised real-world assets into stablecoins on Solana.
Polymarket has partnered with Circle to migrate its platform from bridged USDC on Polygon to Circle-issued native USDC, marking a shift toward direct stablecoin settlement as prediction markets grow.
BioArctic (NASDAQ:B) reported a sharp rise in royalty income for the final quarter of 2025, as the global rollout of its Alzheimer’s treatment Leqembi continues to gain traction across major markets.